ESC Professional Premium Access

Reduction in heart failure hospitalizations by sacubitril/valsartan; a post-hoc analysis of the PARALLAX trial

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Congress Presentation

About the speaker

Associate Professor Rolf Wachter

University hospital Leipzig AoR, Leipzig (Germany)
8 presentations
0 follower

4 more presentations in this session

Trimetazidine in heart failure with preserved ejection fracton: a randomized, double-blind cross-over trial

Speaker: Mr A. van de Bovenkamp (Amsterdam, NL)


Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial

Speaker: Professor J. Butler (Dallas, US)


Association between use of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors and beta-blockers and outcome in real-world heart failure and mildly reduced ejection fraction

Speaker: Doctor F. Lindberg (Stockholm, SE)


The therapeutic potential of relaxin for heart failure with preserved ejection fraction

Speaker: Doctor G. Salama (Pittsburgh, US)


Access the full session

HFpEF and HFmrEF: what’s new in treatment?

Speakers: Associate Professor R. Wachter, Mr A. van de Bovenkamp, Professor J. Butler, Doctor F. Lindberg, Doctor G. Salama

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb